ICCS 2026 puts flow-cytometry-based genotyping beside phenotypic MRD workflows
Summary
The Beckman Coulter ICCS 2026 program includes phenotypic flow cytometry and superRCA flow-cytometer-based genotyping as parallel MRD research workflows.
Source Date
Source checked
October 7, 2026
Event Type
Conference program / workflow integration signal
Event Date
Geography
ICCS 2026, Miami, USA / global research market
Commercial Regulatory Status
Included in the ICCS 2026 program; relevant research workflow components are labelled Research Use Only. An exact completed presentation date is not established by the program.
Related CFCM Topics
ICCS 2026; MRD; Spectral Flow Cytometry; Molecular-Flow Workflows; Automation; Validation & Verification; Technology Radar
Category
Technology
Primary source
Read the source →Facts supported by cited sources
The Beckman Coulter ICCS 2026 program includes a phenotyping research branch using DURAClone RE panels with the CytoFLEX mosaic Spectral Detection Module and a genotyping research branch using superRCA assays with Biomek i-Series automation. The event page labels these components for Research Use Only.
CFCM explainer
Phenotype: cells → antibody panel + spectral flow → cellular phenotype.
Genotype: DNA → superRCA → fluorescent-particle readout on a flow cytometer → variant signal.
Source/credit: CFCM conceptual schematic based on the Beckman Coulter ICCS 2026 program. Alt text: parallel phenotypic and molecular research workflows.
Claims Requiring Caution
Inclusion in a conference program does not establish a completed presentation on a particular day, analytical equivalence between the two research approaches, shared detection limits, a combined diagnostic algorithm, or diagnostic authorization.
Why It Matters
The signal is architectural: flow-cytometry infrastructure is being positioned for both cellular phenotyping and fluorescence readout of molecular assays. The two approaches remain distinct measurements with separate controls and validation requirements.
An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →